1st Counsel – Lifestyle
Author:
Telix Pharmaceuticals Limited
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
April 14, 2026
Telix and Regeneron Announce Strategic Radiopharma Collaboration
April 13, 2026
Telix Strengthens Board with Additional Director Appointments
April 8, 2026
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
April 7, 2026
Telix Appoints David Gill as Non-Executive Director
April 1, 2026
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
March 15, 2026
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
March 9, 2026